Raising the bar: The curative potential of human cancer immunotherapy

Steven A. Rosenberg

doi:10.1126/scitranslmed.3003634

Raising the bar: The curative potential of human cancer immunotherapy

Steven A. Rosenberg

Research output: Contribution to journal › Review article › peer-review

179 Scopus citations

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

Original language	English (US)
Article number	127ps8
Journal	Science translational medicine
Volume	4
Issue number	127
DOIs	https://doi.org/10.1126/scitranslmed.3003634
State	Published - Mar 28 2012
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1126/scitranslmed.3003634

Cite this

@article{bd2a1c42f208453abd603d8caaf69740,

title = "Raising the bar: The curative potential of human cancer immunotherapy",

abstract = "Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.",

author = "Rosenberg, {Steven A.}",

year = "2012",

month = mar,

day = "28",

doi = "10.1126/scitranslmed.3003634",

language = "English (US)",

volume = "4",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "127",

}

TY - JOUR

T1 - Raising the bar

T2 - The curative potential of human cancer immunotherapy

AU - Rosenberg, Steven A.

PY - 2012/3/28

Y1 - 2012/3/28

N2 - Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

AB - Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

UR - http://www.scopus.com/inward/record.url?scp=84859153479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859153479&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003634

DO - 10.1126/scitranslmed.3003634

M3 - Review article

C2 - 22461638

AN - SCOPUS:84859153479

SN - 1946-6234

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 127

M1 - 127ps8

ER -

Raising the bar: The curative potential of human cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this